News 2019 – Levine Media Group

September 18, 2019
Global Genes Report Finds Technology Reshaping the Rare Disease Landscape, but Non-Scientific Challenges Threaten to Impede Progress
The rapid progress of technology is creating an opportunity to improve the prospects many people with rare diseases face today, but patient organizations, drug developers, and other stakeholders need to be innovative in addressing non-scientific challenges to capitalize on the opportunities before them today, a newly released report from Global Genes says.
Read more

June 14, 2019
RARE Webinar: Precision Medicine
Levine Media Group Principal Daniel Levine moderates this Global Genes' webinar on precision medicine. Precision medicine is an emerging approach for disease treatment and prevention that considers individual variability in genes, environment and lifestyle for each person. This approach allows doctors and researchers to predict more accurately which treatment and prevention strategies for a disease will work in which groups of people. This RARE Webinar will provide the rare disease community with information on genetics and precision medicine advancements overall and provide case studies of existing precision medicine use within the community.
Listen to webinar replay

May 28, 2019
Treos Bio Announces Positive Interim Results from a Phase 1/2 Clinical Trial of Precision Cancer Vaccine Plus Maintenance Therapy in Patients with Metastatic Colorectal Cancer
LONDON, May 28, 2019 (GLOBE NEWSWIRE) -- Treos Bio Limited, an immuno-oncology company developing next-generation, precision cancer vaccines combined with companion diagnostic devices, reported positive interim results from its first-in-man Phase 1/2 study of its precision cancer vaccine with maintenance therapy in patients with metastatic colorectal cancer (mCRC).

April 2, 2019
Amfora Licenses Gene Editing Technology
LONDON, May 28, 2019 (GLOBE NEWSWIRE) -- Treos Bio Limited, an immuno-oncology company developing next-generation, precision cancer vaccines combined with companion diagnostic devices, reported positive interim results from its first-in-man Phase 1/2 study of its precision cancer vaccine with maintenance therapy in patients with metastatic colorectal cancer (mCRC).

February 26, 2019
SpineX Names Scientific Advisory Board to Guide Development of Non-Invasive Medical Devices for Neuromodulation of the Spine
LOS ANGELES, Feb. 26, 2019 (GLOBE NEWSWIRE) -- SpineX, a developer of non-invasive medical devices to address a broad range of medical conditions through the neuromodulation of the spinal cord to restore function lost to injury and disease, named a group of leading scientists in the field of neuroscience and medicine to serve on its scientific advisory board.

January 3, 2019
United Soybean Board Awards Grant to Amfora to Increase the Protein Content of U.S. Soy
SAN FRANCISCO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Amfora, a biotechnology company that is applying gene editing to sustainably feed the planet, announced that it has received a grant from the United Soybean Board that the company will use to develop soybean varieties with increased protein content.

Older news